Health Care & Life Sciences » Biotechnology | Genetic Technologies Ltd.

Genetic Technologies Ltd.

Genetic Technologies Ltd.
Stock Exchange Australian Stock Exchange
EPS
 AUD0
Market Cap
 AUD19.02 M
Shares Outstanding
 2.72 B
Public Float
 2.57 B
Genetic Technologies Ltd. ADR
Stock Exchange NASDAQ Stock Market
EPS
 $0.24
Market Cap
 $11.78 M
Shares Outstanding
 18.11 M
Public Float
 -

Profile

Address
60-66 Hanover Street
Fitzroy Victoria (VIC) 3065
Australia
Employees -
Website http://www.gtgcorporate.com
Updated 07/08/2019
Genetic Technologies Ltd. engages in the provision of molecular risk assessment for cancer. It operates through the USA and Australia geographical segments. Its product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer.

Financials

View All
Created with Highcharts 5.0.14Genetic Technologies Ltd.Net Income. Fiscal year is July-June. All values AUD Thousands.10 12510 1258 8108 8108 4598 4598 4038 4035 4635 4632014201520162017201802.5k5k7.5k10k12.5k
Created with Highcharts 5.0.14Genetic Technologies Ltd.Sales/Revenue. Fiscal year is July-June. All values AUD Thousands.4 5644 5642 0112 0118248245185181891892014201520162017201801k2k3k4k5k

Paul Alexander Kasian
Chairman & Chief Executive Officer
Jerzy Muchnicki
Executive Director
View All

StatInvestor

Privacy Policy
Feedback

© 2025 StatInvestor All Rights Reserved.